基本信息
views: 326
Career Trajectory
Bio
Dr. Vonderheide is a distinguished scientist and clinician who has deciphered mechanisms of cancer immune surveillance and developed novel cancer therapeutics, particularly in pancreatic cancer. He is well-recognized for driving the development of agonist CD40 antibodies, now in later stage clinical trials as potential immune therapy of cancer. Dr. Vonderheide discovered telomerase as a universal tumor antigen and has led the efforts to develop telomerase vaccination for both therapy and the prevention of cancer in healthy individuals. He has helped lead a team to show that stereotactic radiation therapy in combination with dual checkpoint blockade represents a synergistic path for immune activation in cancer. Dr. Vonderheide merges his clinical investigations with rigorous studies in mouse models or other laboratory systems. Dr. Vonderheide has been continuously funded by the NCI, and his high-impact findings have been published in Nature, Science, Cell and the New England Journal of Medicine.
RESEARCH INTERESTS
The Vonderheide laboratory combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and to develop novel immunotherapies for cancer. The chief hypothesis is that successful approaches in tumor immunotherapy will need to (a) optimize target antigens with regard to clinical applicability and risk of antigen loss, (b) repair host immuno-incompetence in antigen presentation and T cell function, and (c) circumvent immuno-suppressive factors of the tumor and tumor microenvironment.
RESEARCH DETAILS
Dr. Vonderheide’s basic research includes deciphering the immunobiology of novel genetically engineered mouse models of cancer, including the regulation of immune surveillance and the tumor microenvironment by CD40 and other pathways, and with a focus on pancreatic cancer, breast cancer, and melanoma. His translational work tests novel approaches such as vaccines, antibodies, and adoptive T cells for the treatment of patients with melanoma, pancreatic cancer and other cancers. He has studied ‘universal’ tumor antigens, immune effects of radiation, and immune modulatory pathways involving CD40, GM-CSF, PD-1, CTLA-4, and CD25. Publications include those in high-impact journals such as Nature, Science, Cell, and the New England Journal of Medicine.
RESEARCH INTERESTS
The Vonderheide laboratory combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and to develop novel immunotherapies for cancer. The chief hypothesis is that successful approaches in tumor immunotherapy will need to (a) optimize target antigens with regard to clinical applicability and risk of antigen loss, (b) repair host immuno-incompetence in antigen presentation and T cell function, and (c) circumvent immuno-suppressive factors of the tumor and tumor microenvironment.
RESEARCH DETAILS
Dr. Vonderheide’s basic research includes deciphering the immunobiology of novel genetically engineered mouse models of cancer, including the regulation of immune surveillance and the tumor microenvironment by CD40 and other pathways, and with a focus on pancreatic cancer, breast cancer, and melanoma. His translational work tests novel approaches such as vaccines, antibodies, and adoptive T cells for the treatment of patients with melanoma, pancreatic cancer and other cancers. He has studied ‘universal’ tumor antigens, immune effects of radiation, and immune modulatory pathways involving CD40, GM-CSF, PD-1, CTLA-4, and CD25. Publications include those in high-impact journals such as Nature, Science, Cell, and the New England Journal of Medicine.
Research Interests
Papers共 424 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2024)
crossref(2024)
CANCER RESEARCHno. 2 (2024)
ANNALS OF SURGICAL ONCOLOGYno. 1 (2024): S92-S92
Cited0Views0Bibtex
0
0
Nune Markosyan,Ilkyu Kim,Charu Arora,Noah Cheng, Emma Schechter,John Tobias,Ben Stanger,Robert Vonderheide
Cancer Researchno. 6_Supplement (2024): 4985-4985
Nature communicationsno. 1 (2024): 5763-5763
Cancer Researchno. 6_Supplement (2024): 6597-6597
Elizabeth Ramos,Vivian Nguyen, Ashley Santaniello,Dana Dornsife,Robert G. Johnson,Paul E. Wileyto,Robert H. Vonderheide,Carmen E. Guerra
Cancer Researchno. 6_Supplement (2024): 4825-4825
CANCER RESEARCHno. 2 (2024)
Katelyn T. Byrne,Courtney B. Betts,Rosemarie Mick,Shamilene Sivagnanam,David L. Bajor,Daniel A. Laheru,E. Gabriela Chiorean, Mark H. O'Hara,Shannon M. Liudahl,Craig Newcomb,Cécile Alanio,Ana P. Ferreira,
crossref(2024)
Load More
Author Statistics
#Papers: 423
#Citation: 35976
H-Index: 87
G-Index: 189
Sociability: 8
Diversity: 3
Activity: 121
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn